Month: February 2021

SAN JOSE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — Synaptics Incorporated (Nasdaq: SYNA), today announced its participation in two upcoming investor conferences.Michael Hurlston, President and CEO, will virtually present at the Morgan Stanley Technology, Media and Telecom Conference on March 3, 2021 at 10:15am EST. A live webcast of the presentation will be accessible by visiting Synaptics’ investor website at investor.synaptics.com.Jason Tsai, Head of Investor Relations, will be virtually attending Susquehanna’s Tenth Annual Technology Conference on March 9 and 10, 2021.About Synaptics IncorporatedSynaptics (Nasdaq: SYNA) is changing the way humans engage with connected devices and data, engineering exceptional experiences throughout the home, at work, in the car and on the go. Synaptics is the partner of choice for the world’s...

NEEDHAM, Maine, Feb. 25, 2021 (GLOBE NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, March 4, 2021 at 5:00 pm Eastern Time to discuss financial results for the quarter and year ended December 31, 2020 and to provide a business update.Conference Call DetailsThursday, March 4th@ 5:00 pm Eastern TimeA live audio webcast of the call may also be accessed under “Events & Presentations” on the News & Investors section of the Company’s website, https://ir.chiasma.com/events-presentations. An archived replay of the webcast will be available on the Company’s website approximately two hours after the event. The archived webcast will be available for one year.About ChiasmaChiasma is a commercial...

HAMILTON, Ontario, Feb. 25, 2021 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global telemedicine company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, wishes to inform shareholders that it will be hosting a webinar on March 2, 2021 at 6:00am PST / 9:00am EST to review the Company’s quarterly financial statements for Q2 Fiscal Year 2021 (October 1 – December 31, 2020), and provide a corporate update.Webinar Login Information:For those who are not able to attend the webinar, a recording will be available on the Company’s website (www.reliqhealth.com) immediately following the session.About Reliq HealthReliq Health Technologies is a rapidly growing global telemedicine company that develops innovative...

KB-0742 generated using the company’s proprietary small molecule microarray (SMM) screening platformInitial safety, pharmacokinetic and pharmacodynamic data expected in fourth quarter of 2021SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in the Phase 1/2 clinical trial of KB-0742, a highly selective, orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified solid tumors.“KB-0742 represents a promising new approach to treating cancers that are transcriptionally addicted to MYC. We are excited to have initiated our clinical development program for KB-0742, which emerged from our internal discovery research...

Dallas, Texas, Feb. 25, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — NaturalShrimp, Inc. (OTCQB: SHMP), the aquaculture Company that has developed and patented the first commercially-operational RAS (Recirculating Aquaculture System), announced the recent inspection from the Texas Parks and Wildlife Department.An inspector from the Texas Parks and Wildlife Department visited the NaturalShrimp Facility recently in La Coste, Texas to perform a routine inspection of the facility and the shrimp. After viewing and inspecting the shrimp in various stocked tanks, the inspector submitted a final report saying that the shrimp had full guts and looked healthy. The inspection involved removing a sample of shrimp from the tanks and the inspector determined that none of the shrimp had issues with the following:·         Empty guts·        ...

MONTREAL, Feb. 25, 2021 (GLOBE NEWSWIRE) — Niobay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY; OTCQB: NBYCF) is pleased to announce that its common shares are now trading on the OTCQB Venture Market, a U.S. market operated by OTC Markets Group Inc. (“OTC”) in New York, under the symbol “NBYCF’’. NioBay will continue to trade on the TSX Venture Exchange under its symbol “NBY”.“NioBay’s OTCQB listing is an important step to provide easier access and trading capability in our Company’s shares for both institutional and retail investors,” stated Claude Dufresne, President and CEO of NioBay. “This provides NioBay with a platform to expand our U.S. shareholder profile and allow a broader group of investors to participate in the niobium market.”The OTC operates the world’s largest electronic interdealer quotation system for US...

MONTRÉAL, 25 févr. 2021 (GLOBE NEWSWIRE) — Les Métaux NioBay inc. (« NioBay » ou la « Société ») (TSX-V: NBY; OTCQB : NBYCF) a le plaisir d’annoncer que ses actions ordinaires se transigent maintenant sur le OTCQB Venture Market, un marché américain exploité par OTC Markets Group Inc. (« OTC ») à New York, sous le symbole « NBYCF ». NioBay continuera de se négocier à la Bourse de croissance TSX sous son symbole « NBY ».« L’inscription de NioBay à l’OTCQB est une étape importante pour faciliter l’accès et la capacité de négociation des actions de notre société aux investisseurs institutionnels et particuliers », a déclaré Claude Dufresne, président et chef de la direction de NioBay. « Cela fournit à NioBay une plate-forme pour élargir le profil de nos actionnaires américains et permettre à un groupe plus large d’investisseurs de...

MONTREAL, Feb. 25, 2021 (GLOBE NEWSWIRE) — Innovative silicon solutions provider HPQ Silicon Resources Inc. (“HPQ” or the “Company”) (TSX-V: HPQ; FWB: UGE; Other OTC :HPQFF), is proud to announce that it has received the TREKHY® system, a portable hydrogen-based mini-power generator, jointly developed by the French companies Apollon Solar SAS (“Apollon”) and Pragma Industries SAS (“Pragma”). While continuing to work with Apollon on the development of new generations of more efficient silicon powders for hydrogen production, HPQ signed a Memorandum of Understanding with Apollon and Pragma to study the commercial potential of the TREKHY® autonomous power generator in Canada.The portable hydrogen-based power generator, a revolutionary productThe TREKHY® provides energy on demand. The system uses a compact fuel cell to provide electrical...

MONTRÉAL, 25 févr. 2021 (GLOBE NEWSWIRE) — Le fournisseur de solutions innovantes à base de silicium Ressources HPQ Silicium inc. (« HPQ » ou « la Société ») (TSX-V : HPQ ; FWB : UGE ; Autre OTC : HPQFF), est heureux d’annoncer la réception du système TREKHY®, un mini-groupe électrogène portable à base d’hydrogène, développé conjointement par les sociétés françaises Apollon Solar SAS (« Apollon ») et Pragma Industries SAS (« Pragma »). Tout en continuant le travail avec Apollon sur le développement de nouvelles générations de poudres de silicium plus performantes pour la production d’hydrogène, HPQ a signé un protocole d’entente avec Apollon et Pragma dans le but d’étudier le potentiel commercial du générateur portable d’énergie TREKHY® au Canada.Le générateur portable d’énergie à base d’hydrogène, un produit révolutionnaireLe TREKHY®...

Blinded interim data from VISIONARY-MS continue to support the potential of CNM-Au8 to drive meaningful neurological functional improvements in MS patientsInterim REPAIR-MS results provide further evidence of CNM-Au8’s homeostatic effect on brain bioenergetics in MS patientsSALT LAKE CITY, Feb. 25, 2021 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, will present blinded interim data from its VISIONARY-MS study and updated interim data from its REPAIR-MS study in on-demand presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) ACTRIMS Forum 2021 taking place virtually from February 25-27, 2021. Together, these complementary Phase 2...